TY - JOUR
T1 - Identification of novel pathways and immune profiles related to sarcopenia
AU - Abdelrahman, Zeinab
AU - Wang, Xiaosheng
AU - Wang, Daming
AU - Zhang, Tianfang
AU - Zhang, Yue
AU - Wang, Xuhua
AU - Chen, Zuobing
N1 - Copyright © 2023 Abdelrahman, Wang, Wang, Zhang, Zhang, Wang and Chen.
PY - 2023/4/17
Y1 - 2023/4/17
N2 - INTRODUCTION: Sarcopenia is a progressive deterioration of skeletal muscle mass strength and function.METHODS: To uncover the underlying cellular and biological mechanisms, we studied the association between sarcopenia's three stages and the patient's ethnicity, identified a gene regulatory network based on motif enrichment in the upregulated gene set of sarcopenia, and compared the immunological landscape among sarcopenia stages.RESULTS: We found that sarcopenia (S) was associated with GnRH, neurotrophin, Rap1, Ras, and p53 signaling pathways. Low muscle mass (LMM) patients showed activated pathways of VEGF signaling, B-cell receptor signaling, ErbB signaling, and T-cell receptor signaling. Low muscle mass and physical performance (LMM_LP) patients showed lower enrichment scores in B-cell receptor signaling, apoptosis, HIF-1 signaling, and the adaptive immune response pathways. Five common genes among DEGs and the elastic net regression model,
TTC39DP, SLURP1, LCE1C, PTCD2P1, and
OR7E109P, were expressed between S patients and healthy controls.
SLURP1 and
LCE1C showed the highest expression levels among sarcopenic Chinese descent than Caucasians and Afro-Caribbeans. Gene regulatory analysis of top upregulated genes in S patients yielded a top-scoring regulon containing GATA1, GATA2, and GATA3 as master regulators and nine predicted direct target genes. Two genes were associated with locomotion:
POSTN and
SLURP1.
TTC39DP upregulation was associated with a better prognosis and stronger immune profile in S patients. The upregulation of
SLURP1 and
LCE1C was associated with a worse prognosis and weaker immune profile.
CONCLUSION: This study provides new insight into sarcopenia's cellular and immunological prospects and evaluates the age and sarcopenia-related modifications of skeletal muscle.
AB - INTRODUCTION: Sarcopenia is a progressive deterioration of skeletal muscle mass strength and function.METHODS: To uncover the underlying cellular and biological mechanisms, we studied the association between sarcopenia's three stages and the patient's ethnicity, identified a gene regulatory network based on motif enrichment in the upregulated gene set of sarcopenia, and compared the immunological landscape among sarcopenia stages.RESULTS: We found that sarcopenia (S) was associated with GnRH, neurotrophin, Rap1, Ras, and p53 signaling pathways. Low muscle mass (LMM) patients showed activated pathways of VEGF signaling, B-cell receptor signaling, ErbB signaling, and T-cell receptor signaling. Low muscle mass and physical performance (LMM_LP) patients showed lower enrichment scores in B-cell receptor signaling, apoptosis, HIF-1 signaling, and the adaptive immune response pathways. Five common genes among DEGs and the elastic net regression model,
TTC39DP, SLURP1, LCE1C, PTCD2P1, and
OR7E109P, were expressed between S patients and healthy controls.
SLURP1 and
LCE1C showed the highest expression levels among sarcopenic Chinese descent than Caucasians and Afro-Caribbeans. Gene regulatory analysis of top upregulated genes in S patients yielded a top-scoring regulon containing GATA1, GATA2, and GATA3 as master regulators and nine predicted direct target genes. Two genes were associated with locomotion:
POSTN and
SLURP1.
TTC39DP upregulation was associated with a better prognosis and stronger immune profile in S patients. The upregulation of
SLURP1 and
LCE1C was associated with a worse prognosis and weaker immune profile.
CONCLUSION: This study provides new insight into sarcopenia's cellular and immunological prospects and evaluates the age and sarcopenia-related modifications of skeletal muscle.
U2 - 10.3389/fmed.2023.928285
DO - 10.3389/fmed.2023.928285
M3 - Article
C2 - 37138756
SN - 2296-858X
VL - 10
JO - Frontiers in Medicine
JF - Frontiers in Medicine
M1 - 928285
ER -